{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T11:29:27Z","timestamp":1787311767586,"version":"build-2736575974"},"reference-count":70,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T00:00:00Z","timestamp":1787270400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>The discovery of the Janus kinase\/signal transducer and activator of transcription (JAK\/STAT) pathway as a key regulator of immune function and inflammation led to the development of JAK inhibitors (JAK-i), several of which are now approved for autoimmune and chronic inflammatory conditions. Recently, JAK-i have been repurposed for infectious diseases, most notably with baricitinib, a United States Food and Drug Administration (FDA)-approved JAK1\/2 inhibitor for individuals hospitalized for COVID-19, demonstrating a survival benefit by dampening cytokine-mediated hyperinflammation. This has generated increased interest in leveraging JAK-i for treating people with viral infections associated with chronic immune activation, inflammation or viral persistence. This review summarizes JAK\/STAT signaling in viral infections characterized by latency or chronic sequelae. We explore how modulation of this pathway may alter immune responses, impact viral control, and mitigate the consequences of chronic inflammation. We also critically examine the therapeutic potential and limitations of JAK-i in these contexts. Finally, we outline key gaps in the field and propose future directions for research into JAK\/STAT targeted immunomodulation in chronic viral infections.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1887876","type":"journal-article","created":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:54:06Z","timestamp":1787309646000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting the JAK\/STAT pathway in chronic viral infections: opportunities and challenges for immunomodulation"],"prefix":"10.3389","volume":"17","author":[{"given":"Nathalie","family":"Garnier","sequence":"first","affiliation":[{"name":"Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Children\u2019s Healthcare of Atlanta","place":["Atlanta, GA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Ossi","sequence":"additional","affiliation":[{"name":"Department of Medicine, Emory University School of Medicine","place":["Atlanta, GA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent C.","family":"Marconi","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Emory University School of Medicine","place":["Atlanta, GA, United States"]},{"name":"Department of Global Health, Rollins School of Public Health","place":["Atlanta, GA, United States"]},{"name":"Emory Vaccine Center, Emory University","place":["Atlanta, GA, United States"]},{"name":"The Joseph Maxwell Cleland Atlanta VA Medical Center, The Atlanta Veterans Affairs Medical Center","place":["Decatur, GA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond F.","family":"Schinazi","sequence":"additional","affiliation":[{"name":"Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Children\u2019s Healthcare of Atlanta","place":["Atlanta, GA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boghuma K.","family":"Titanji","sequence":"additional","affiliation":[{"name":"Center for ViroScience and Cure, Laboratory of Biochemical Pharmacology, Department of Pediatrics, Emory University School of Medicine and Children\u2019s Healthcare of Atlanta","place":["Atlanta, GA, United States"]},{"name":"Division of Infectious Diseases, Emory University School of Medicine","place":["Atlanta, GA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1135145","article-title":"Therapeutic implications of current Janus kinase inhibitors as anti-COVID agents: a review","volume":"14","author":"Jain","year":"2023","journal-title":"Front Pharmacol"},{"key":"B2","doi-asserted-by":"crossref","DOI":"10.1201\/9781351042468-14","article-title":"Targeting JAK-STAT pathway for various inflammatory diseases and viral infections","volume-title":"JAK-STAT Signaling in Diseases","author":"Gavegnano","year":"2020"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/eji.202048922","article-title":"JAK inhibitors: ten years after","volume":"51","author":"Spinelli","year":"2021","journal-title":"Eur J Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.revmed.2024.10.452","article-title":"JAK inhibitors (JAKi): mechanisms of action and perspectives in systemic and autoimmune diseases","volume":"46","author":"Chikhoune","year":"2025","journal-title":"Rev M\u00e9decine Interne"},{"key":"B5","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1093\/cid\/ciab212","article-title":"Randomized trial of ruxolitinib in antiretroviral-treated adults with human immunodeficiency virus","volume":"74","author":"Marconi","year":"2022","journal-title":"Clin Infect Dis"},{"key":"B6","unstructured":"A multicenter, adaptive, randomized blinded controlled trial of the safety and efficacy of investigational therapeutics for the treatment of COVID-19 in hospitalized adults (ACTT-2)\n          \n          \n          \n          2022"},{"key":"B7","unstructured":"A multicenter, adaptive, randomized blinded controlled trial of the safety and efficacy of investigational therapeutics for the treatment of COVID-19 in hospitalized adults (ACTT-4)\n          \n          \n          \n          2022"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01109-6","article-title":"Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis","volume":"400","year":"2022","journal-title":"Lancet Lond Engl"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(25)00055-4","article-title":"Effects of Janus kinase inhibitors in adults admitted to hospital due to COVID-19: a systematic review and individual participant data meta-analysis of randomised clinical trials","volume":"13","author":"Amstutz","year":"2025","journal-title":"Lancet Respir Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens14040324","article-title":"The dual-edged sword: risks and benefits of JAK inhibitors in infections","volume":"14","author":"Jarneborn","year":"2025","journal-title":"Pathogens"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.revmed.2025.06.003","article-title":"Safety profile of JAK inhibitors in inflammatory or autoimmune diseases","volume":"46","author":"Moreau","year":"2025","journal-title":"Rev Med Interne"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s11938-025-00484-6","article-title":"How to safely use JAK inhibitors in patients with inflammatory bowel disease","volume":"23","author":"Loganantharaj","year":"2025","journal-title":"Curr Treat Options Gastroenterol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26189123","article-title":"The STAT signaling pathway in HIV-1 infection: roles and dysregulation","volume":"26","author":"Tolomeo","year":"2025","journal-title":"Int J Mol Sci"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.014873","article-title":"Targeting inflammation to reduce atherosclerotic cardiovascular risk in people with HIV infection","volume":"9","author":"Titanji","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adl0368","article-title":"JAK\/STAT signaling pathway affects CCR5 expression in human CD4+ T cells","volume":"10","author":"Wang","year":"2024","journal-title":"Sci Adv"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006740","article-title":"Novel mechanisms to inhibit HIV reservoir seeding using Jak inhibitors","volume":"13","author":"Gavegnano","year":"2017","journal-title":"PloS Pathog"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03277-z","article-title":"Sustained HIV remission after allogeneic hematopoietic stem cell transplantation with wild-type CCR5 donor cells","volume":"30","author":"S\u00e1ez-Ciri\u00f3n","year":"2024","journal-title":"Nat Med"},{"key":"B19","unstructured":"Ruxolitinib-mediated HIV-1 reservoir decay in A5336 phase 2a trial\n          \n          \n            \n              Reece\n              MD\n            \n            \n              Zhang\n              Z\n            \n            \n              Ribeiro\n              RM\n            \n            \n              Pereira-Ribeiro\n              S\n            \n            \n              Kulpa\n              DA\n            \n            \n              White\n              E\n            \n          \n          \n          2024"},{"key":"B20","unstructured":"Phase II study to evaluate the efficacy and safety of baricitinib for reduction of HIV in the central nervous system\n          \n          \n            \n              Tyor\n              W\n            \n          \n          Clinicaltrials.Gov\n          \n          2025"},{"key":"B21","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1186\/s12974-019-1565-6","article-title":"Baricitinib reverses HIV-associated neurocognitive disorders in a SCID mouse model and reservoir seeding in vitro","volume":"16","author":"Gavegnano","year":"2019","journal-title":"J Neuroinflamm"},{"key":"B22","unstructured":"Baricitinib curative repression of HIV-1\n          \n          \n            \n              Marconi\n              V\n            \n          \n          Clinicaltrials.Gov\n          \n          2025"},{"key":"B23","unstructured":"The role of inflammation in central nervous system (CNS) mechanisms of anhedonia and psychomotor slowing in depressed people with HIV\n          \n          \n            \n              Miller\n              AH\n            \n          \n          Clinicaltrials.Gov\n          \n          2025"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2020.100913","article-title":"Enhanced efficacy of JAK1 inhibitor with mTORC1\/C2 targeting in smoldering\/chronic adult T cell leukemia","volume":"14","author":"Daenthanasanmak","year":"2021","journal-title":"Transl Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s10456-021-09805-6","article-title":"COVID-19 is a systemic vascular hemopathy: insight for mechanistic and clinical aspects","volume":"24","author":"Smadja","year":"2021","journal-title":"Angiogenesis"},{"key":"B26","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41392-022-01249-8","article-title":"Small molecules in the treatment of COVID-19","volume":"7","author":"Lei","year":"2022","journal-title":"Signal Transduct Target Ther"},{"key":"B27","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1080\/25785826.2025.2570902","article-title":"Long COVID: mechanisms of disease, multisystem sequelae, and prospects for treatment","volume":"49","author":"Oba","year":"2025","journal-title":"Immunol Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2024.07.054","article-title":"Mechanisms of long COVID and the path toward therapeutics","volume":"187","author":"Peluso","year":"2024","journal-title":"Cell"},{"key":"B29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1038\/s41590-025-02353-x","article-title":"Long COVID involves activation of proinflammatory and immune exhaustion pathways","volume":"27","author":"Aid","year":"2026","journal-title":"Nat Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.3390\/v14091991","article-title":"SARS-CoV-2 non-structural proteins and their roles in host immune evasion","volume":"14","author":"Low","year":"2022","journal-title":"Viruses"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(22)00044-3","article-title":"Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"4","author":"Han","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(23)00376-4","article-title":"Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial","volume":"11","author":"Hall","year":"2023","journal-title":"Lancet Respir Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1589589","article-title":"Comprehensive transcriptome assessment in PBMCs of post-COVID patients at a median follow-up of 28 months after a mild COVID infection reveals upregulation of JAK\/STAT signaling and a prolonged immune response","volume":"16","author":"Fineschi","year":"2025","journal-title":"Front Immunol"},{"key":"B34","unstructured":"Randomized double-blind placebo-controlled trial evaluating baricitinib on persistent neurologic and cardiopulmonary symptoms of long COVID (REVERSE-LC)\n          \n          \n            \n              Ely\n              W\n            \n          \n          Clinicaltrials.Gov\n          \n          2025"},{"key":"B35","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1186\/s12883-025-04341-y","article-title":"Favorable responses to upadacitinib, a JAK1 inhibitor, in long COVID patients with predominant neuropsychiatric symptoms: case reports in 2 autistic patients and one typically developing patient","volume":"25","author":"Jyonouchi","year":"2025","journal-title":"BMC Neurol"},{"key":"B36","unstructured":"Improvement in long COVID symptoms in two individuals treated with baricitinib\n          \n          \n            \n              Llad\u00f3s\n              G\n            \n            \n              Marconi\n              VC\n            \n            \n              Ely\n              EW\n            \n            \n              Peluso\n              MJ\n            \n            \n              Gavegnano\n              C\n            \n            \n              Hsue0\n              PY\n            \n          \n          Ann Case Rep\n          \n          2024"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.2217\/fvl-2018-0033","article-title":"STAT3 roles in viral infection: antiviral or proviral","volume":"13","author":"Chang","year":"2018","journal-title":"Future Virol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10123202","article-title":"Pathogenesis and current treatment strategies of hepatocellular carcinoma","volume":"10","author":"T\u00fcmen","year":"2022","journal-title":"Biomedicines"},{"key":"B39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12985-021-01544-w","article-title":"The role of SOCS proteins in the development of virus-induced hepatocellular carcinoma","volume":"18","author":"Xie","year":"2021","journal-title":"Virol J"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.10.030","article-title":"JAK1 promotes HDV replication and is a potential target for antiviral therapy","volume":"80","author":"Heuschkel","year":"2024","journal-title":"J Hepatol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12967-022-03366-y","article-title":"Ruxolitinib suppresses liver fibrosis progression and accelerates fibrosis reversal via selectively targeting Janus kinase 1\/2","volume":"20","author":"Song","year":"2022","journal-title":"J Transl Med"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201900215RR","article-title":"TG101348, a selective JAK2 antagonist, ameliorates hepatic fibrogenesis in vivo","volume":"33","author":"Akcora","year":"2019","journal-title":"FASEB J Off Publ Fed Am Soc Exp Biol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32746","article-title":"Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis","volume":"77","author":"Torres","year":"2023","journal-title":"Hepatol Baltim Md"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.14309\/crj.0000000000001327","article-title":"Upadacitinib-induced hepatitis B reactivation leading to liver transplant","volume":"11","author":"Khan","year":"2024","journal-title":"ACG Case Rep J"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M116.773085","article-title":"Transforming growth factor-\u03b2 (TGF-\u03b2) directly activates the JAK1-STAT3 axis to induce hepatic fibrosis in coordination with the SMAD pathway","volume":"292","author":"Tang","year":"2017","journal-title":"J Biol Chem"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.3390\/cells8111419","article-title":"TGF-\u03b2 in hepatic stellate cell activation and liver fibrogenesis-updated 2019","volume":"8","author":"Dewidar","year":"2019","journal-title":"Cells"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/nri1604","article-title":"Mechanisms of type-I- and type-II-interferon-mediated signalling","volume":"5","author":"Platanias","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1089\/jir.2023.0039","article-title":"Synthetic heterodimers of type III interferon receptors require TYK2 for STAT activation","volume":"43","author":"Mesev","year":"2023","journal-title":"J Interferon Cytokine Res Off J Int Soc Interferon Cytokine Res"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.3390\/v13122344","article-title":"Molecular basis of Epstein\u2013Barr virus latency establishment and lytic reactivation","volume":"13","author":"Murata","year":"2021","journal-title":"Viruses"},{"key":"B50","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/35095584","article-title":"Epstein-Barr virus: exploiting the immune system","volume":"1","author":"Thorley-Lawson","year":"2001","journal-title":"Nat Rev Immunol"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12529","article-title":"Tofacitinib induces G1 cell-cycle arrest and inhibits tumor growth in Epstein-Barr virus-associated T and natural killer cell lymphoma cells","volume":"7","author":"Ando","year":"2016","journal-title":"Oncotarget"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2018.1512709","article-title":"The JAK inhibitor antcin H exhibits direct anticancer activity while enhancing chemotherapy against LMP1-expressed lymphoma","volume":"60","author":"Chen","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.710400","article-title":"Ruxolitinib in patients with chronic active Epstein-Barr virus infection: A retrospective, single-center study","volume":"12","author":"Song","year":"2021","journal-title":"Front Pharmacol"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2024.100053","article-title":"JAK1\/2 inhibitor ruxolitinib for the treatment of systemic chronic active Epstein-Barr virus disease: a phase 2 study","volume":"2","author":"Uemura","year":"2025","journal-title":"Blood Neoplasia"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.25744","article-title":"Cytomegalovirus, Epstein-Barr virus, and human herpesvirus-6 infections in patients with myalgic \u0435ncephalomyelitis\/chronic fatigue syndrome","volume":"92","author":"Shikova","year":"2020","journal-title":"J Med Virol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1186\/s12967-018-1644-y","article-title":"Chronic viral infections in myalgic encephalomyelitis\/chronic fatigue syndrome (ME\/CFS)","volume":"16","author":"Rasa","year":"2018","journal-title":"J Transl Med"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13237124","article-title":"Lights and shadows of long COVID: Are latent infections the real hidden enemy","volume":"13","author":"Serapide","year":"2024","journal-title":"J Clin Med"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1172\/JCI163669","article-title":"Chronic viral coinfections differentially affect the likelihood of developing long COVID","volume":"133","author":"Peluso","year":"2023","journal-title":"J Clin Invest"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-090668","article-title":"Optimal timing of recombinant herpes zoster virus vaccination for a JAK inhibitor treatment in rheumatoid arthritis: a multicentre, open-label, randomised comparative study (STOP-HZ study): study protocol","volume":"14","author":"Takanashi","year":"2024","journal-title":"BMJ Open"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1055\/s-0036-1584793","article-title":"Herpesvirus respiratory infections in immunocompromised patients: Epidemiology, management, and outcomes","volume":"37","author":"Reid","year":"2016","journal-title":"Semin Respir Crit Care Med"},{"key":"B61","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s40674-025-00235-9","article-title":"Risk of herpes zoster and opportunistic infections with treatments for autoimmune rheumatic disease","volume":"11","author":"Yeo","year":"2025","journal-title":"Curr Treat Options Rheumatol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad060","article-title":"Effect of immune-modulatory interventions on asymptomatic cytomegalovirus shedding during suppressive antiretroviral therapy","volume":"228","author":"Hastie","year":"2023","journal-title":"J Infect Dis"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2024.152362","article-title":"Continued JAK inhibitor treatment on the risk of recurrent herpes zoster reactivation in patients with immune-mediated inflammatory diseases: A nationwide population-based study in South Korea","volume":"65","author":"Kim","year":"2024","journal-title":"Semin Arthritis Rheum"},{"key":"B64","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12979-025-00533-9","article-title":"The impacts of chronic infections on shaping cellular senescence","volume":"22","author":"Johnson","year":"2025","journal-title":"Immun Ageing A"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/s2666-7568(21)00278-6","article-title":"Biological ageing with HIV infection: evaluating the geroscience hypothesis","volume":"3","author":"Montano","year":"2022","journal-title":"Lancet Healthy Longev"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1016\/j.cancergencyto.2008.08.006","article-title":"Telomere length in hepatitis C","volume":"187","author":"Kitay-Cohen","year":"2008","journal-title":"Cancer Genet Cytogenet"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/glae232","article-title":"Accelerated phenotypic aging associated with hepatitis C infection: Results from the U.S. National Health and Nutrition Examination Surveys 2015-2018","volume":"79","author":"Tao","year":"2024","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2023.1229098","article-title":"Contribution of viral and bacterial infections to senescence and immunosenescence","volume":"13","author":"Reyes","year":"2023","journal-title":"Front Cell Infect Microbiol"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2016.05.015","article-title":"Perspective: Targeting the JAK\/STAT pathway to fight age-related dysfunction","volume":"111","author":"Xu","year":"2016","journal-title":"Pharmacol Res"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.96489","article-title":"Ruxolitinib-based senomorphic therapy mitigates cardiomyocyte senescence in septic cardiomyopathy by inhibiting the JAK2\/STAT3 signaling pathway","volume":"20","author":"Yang","year":"2024","journal-title":"Int J Biol Sci"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1887876\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T10:54:08Z","timestamp":1787309648000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1887876\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,21]]},"references-count":70,"alternative-id":["10.3389\/fimmu.2026.1887876"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1887876","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,21]]},"article-number":"1887876"}}